201 related articles for article (PubMed ID: 36895385)
1. Prognostic value of genomic mutations in metastatic prostate cancer.
Zhu H; Ding Y; Huang H; Lin Q; Chen W; Yu Z
Heliyon; 2023 Mar; 9(3):e13827. PubMed ID: 36895385
[TBL] [Abstract][Full Text] [Related]
2. Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study.
Dong B; Fan L; Yang B; Chen W; Li Y; Wu K; Zhang F; Dong H; Cheng H; Pan J; Zhu Y; Chi C; Dong L; Sha J; Li L; Yao X; Xue W
J Natl Compr Canc Netw; 2021 May; 19(8):905-914. PubMed ID: 33990090
[TBL] [Abstract][Full Text] [Related]
3. Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies.
Zurita AJ; Graf RP; Villacampa G; Raskina K; Sokol E; Jin D; Antonarakis ES; Li G; Huang RSP; Casanova-Salas I; Vivancos A; Carles J; Ross JS; Schrock AB; Oxnard GR; Mateo J
JCO Precis Oncol; 2022 Jul; 6():e2200195. PubMed ID: 35820087
[TBL] [Abstract][Full Text] [Related]
4.
Warner E; Herberts C; Fu S; Yip S; Wong A; Wang G; Ritch E; Murtha AJ; Vandekerkhove G; Fonseca NM; Angeles A; Beigi A; Schönlau E; Beja K; Annala M; Khalaf D; Chi KN; Wyatt AW
Clin Cancer Res; 2021 Mar; 27(6):1650-1662. PubMed ID: 33414135
[TBL] [Abstract][Full Text] [Related]
5. Comparative Analysis of Genomic Alterations across Castration Sensitive and Castration Resistant Prostate Cancer via Circulating Tumor DNA Sequencing.
Fan L; Fei X; Zhu Y; Pan J; Sha J; Chi C; Gong Y; Du X; Zhou L; Dong B; Xue W
J Urol; 2021 Feb; 205(2):461-469. PubMed ID: 32897803
[TBL] [Abstract][Full Text] [Related]
6. Primary Mutational Landscape Linked with Pre-Docetaxel Lactate Dehydrogenase Levels Predicts Docetaxel Response in Metastatic Castrate-Resistant Prostate Cancer.
Hiew K; Hart CA; Ali A; Elliott T; Ramani V; Sangar V; Lau M; Maddineni S; Brown M; Clarke N
Eur Urol Focus; 2019 Sep; 5(5):831-841. PubMed ID: 29699892
[TBL] [Abstract][Full Text] [Related]
7. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
Dariane C; Timsit MO
Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
[TBL] [Abstract][Full Text] [Related]
8. Distinct Response to Platinum-Based Chemotherapy among Patients with Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
Fan L; Fei X; Zhu Y; Chi C; Pan J; Sha J; Xin Z; Gong Y; Du X; Wang Y; Dong B; Xue W
J Urol; 2021 Sep; 206(3):630-637. PubMed ID: 33904759
[TBL] [Abstract][Full Text] [Related]
9. Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes.
Hwang J; Shi X; Elliott A; Arnoff TE; McGrath J; Xiu J; Walker P; Bergom HE; Day A; Ahmed S; Tape S; Makovec A; Ali A; Shaker RM; Toye E; Passow R; Lozada JR; Wang J; Lou E; Mouw KW; Carneiro BA; Heath EI; McKay RR; Korn WM; Nabhan C; Ryan CJ; Antonarakis ES
Clin Cancer Res; 2023 Jul; 29(14):2702-2713. PubMed ID: 37126020
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.
Reimers MA; Yip SM; Zhang L; Cieslik M; Dhawan M; Montgomery B; Wyatt AW; Chi KN; Small EJ; Chinnaiyan AM; Alva AS; Feng FY; Chou J
Eur Urol; 2020 Mar; 77(3):333-341. PubMed ID: 31640893
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.
Sokolova AO; Marshall CH; Lozano R; Gulati R; Ledet EM; De Sarkar N; Grivas P; Higano CS; Montgomery B; Nelson PS; Olmos D; Sokolov V; Schweizer MT; Yezefski TA; Yu EY; Paller CJ; Sartor O; Castro E; Antonarakis ES; Cheng HH
Prostate; 2021 Dec; 81(16):1382-1389. PubMed ID: 34516663
[TBL] [Abstract][Full Text] [Related]
12. Homologous recombination repair gene mutations in Chinese localized and locally advanced prostate cancer patients.
Jiang X; Hu X; Gu Y; Li Y; Jin M; Zhao H; Gao R; Huang Z; Lu J
Pathol Res Pract; 2021 Aug; 224():153507. PubMed ID: 34102435
[TBL] [Abstract][Full Text] [Related]
13. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and Prognostic Relevance of Homologous Recombination Repair Gene Mutations in Uterine Serous Carcinoma.
Dong L; Wang T; Li N; Yao H; Ying J; Wu L; Yuan G
Cells; 2022 Nov; 11(22):. PubMed ID: 36428992
[TBL] [Abstract][Full Text] [Related]
15. Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes.
Walsh EM; Mangini N; Fetting J; Armstrong D; Chan IS; Connolly RM; Fiallos K; Lehman J; Nunes R; Petry D; Reynolds J; Shah M; Smith KL; Visvanathan K; Lauring J; Park BH; Stearns V; Wolff AC
Clin Breast Cancer; 2022 Jun; 22(4):319-325. PubMed ID: 35074264
[TBL] [Abstract][Full Text] [Related]
16. Somatic and germline aberrations in homologous recombination repair genes in Chinese prostate cancer patients.
Liu Y; Jin B; Shen C; Gao X; Qi X; Ma M; Li H; Hao H; Tang Q; Yang K; Mi Y; Guan J; Feng X; He Z; Li H; Yu W
Front Oncol; 2023; 13():1086517. PubMed ID: 37064136
[TBL] [Abstract][Full Text] [Related]
17.
Antonarakis ES; Isaacsson Velho P; Fu W; Wang H; Agarwal N; Sacristan Santos V; Maughan BL; Pili R; Adra N; Sternberg CN; Vlachostergios PJ; Tagawa ST; Bryce AH; McNatty AL; Reichert ZR; Dreicer R; Sartor O; Lotan TL; Hussain M
JCO Precis Oncol; 2020; 4():370-381. PubMed ID: 32462107
[TBL] [Abstract][Full Text] [Related]
18. Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer.
Ritch E; Fu SYF; Herberts C; Wang G; Warner EW; Schönlau E; Taavitsainen S; Murtha AJ; Vandekerkhove G; Beja K; Loktionova Y; Khalaf D; Fazli L; Kushnir I; Ferrario C; Hotte S; Annala M; Chi KN; Wyatt AW
Clin Cancer Res; 2020 Mar; 26(5):1114-1125. PubMed ID: 31744831
[TBL] [Abstract][Full Text] [Related]
19. Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.
Nizialek E; Lim SJ; Wang H; Isaacsson Velho P; Yegnasubramanian S; Antonarakis ES
Prostate; 2021 Jun; 81(9):572-579. PubMed ID: 33955569
[TBL] [Abstract][Full Text] [Related]
20. DNA damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries.
Abdi B; Basset N; Perrot E; Benderra MA; Khalil A; Oudard S; Blanchet P; Brureau L; Coulet F; Cussenot O; Cancel-Tassin G
Prostate; 2022 Sep; 82(12):1196-1201. PubMed ID: 35652560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
